In vivo short hairpin RNA interference of vascular endothelial growth factor on drug-resistant tongue cancer cells.
- Author:
Xiao-Lin NONG
1
;
Hao LI
;
Yong XIA
;
Yan LI
;
Jia-Quan LI
;
Yi-Ping YANG
Author Information
- Publication Type:Journal Article
- MeSH: ATP-Binding Cassette, Sub-Family B, Member 1; metabolism; Animals; Carcinoma, Squamous Cell; metabolism; pathology; Cell Line, Tumor; Cell Proliferation; Cisplatin; pharmacology; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; pathology; Mitogen-Activated Protein Kinase 1; metabolism; Proto-Oncogene Proteins c-bcl-2; metabolism; RNA Interference; RNA, Messenger; metabolism; RNA, Small Interfering; genetics; Random Allocation; Tongue Neoplasms; metabolism; pathology; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; genetics; metabolism; Xenograft Model Antitumor Assays
- From: Chinese Journal of Stomatology 2011;46(1):15-19
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the in vivo interference effects of vascular endothelial growth factor (VEGF) short hairpin RNA (shRNA) on xenografts of drug-resistant tongue cancer cells.
METHODSDrug-resistant tongue caner cells Tca/Cisplatin (DDP) were injected subcutaneously into nude mice to establish xenograft models, which were randomly divided into non-transfected group, mock control group, control group transfected with scrambled sequence plasmid, interference group transfected with VEGF-shRNA expression plasmid. Liposome-mediated plasmid transfection was done in the latter three groups every three days. Xenografts were observed and tumor growth curve was measured. After the 10th transfection, tumors were anatomized and weigh. Microvessel density was detected by immunohistochemical staining. In situ hybridization assay was used to test VEGF mRNA, and immunohistochemistry to test VEGF, P-glycoprotein (P-gp), B cell lymphoma/leukemia-2 (bcl-2) and extracellular signal-regultaed kinase 2 (ERK-2) protein.
RESULTSTumor growth in VEGF-shRNA interference group was significantly slow. Tumor weight was (0.4781 ± 0.0860) g, microvessel density (7.35 ± 1.31)/view, VEGF mRNA (0.0767 ± 0.0234), VEGF protein (0.1301 ± 0.0433), P-gp (0.1517 ± 0.0184), bcl-2 (0.1218 ± 0.0251) and ERK-2 protein (0.1178 ± 0.0291) in VEGF-shRNA interference group; all of them were less than those in the other three groups (P < 0.05).
CONCLUSIONSInhibition targeting VEGF may become a potential therapy for drug-resistant tongue cancer.
